Agenus (NASDAQ:AGEN) Rating Reiterated by HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 248.74% from the stock’s current price.

Several other analysts have also weighed in on AGEN. B. Riley decreased their price objective on Agenus from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 18th. StockNews.com initiated coverage on shares of Agenus in a report on Wednesday, April 17th. They issued a “hold” rating on the stock.

Agenus Trading Down 4.5 %

Shares of Agenus stock opened at $11.47 on Tuesday. Agenus has a 1 year low of $4.78 and a 1 year high of $42.60. The company’s fifty day simple moving average is $10.71 and its 200-day simple moving average is $13.23. The company has a market cap of $232.67 million, a price-to-earnings ratio of -0.81 and a beta of 1.25.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The business had revenue of $83.80 million for the quarter, compared to the consensus estimate of $54.21 million. As a group, research analysts forecast that Agenus will post -8.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Garo H. Armen bought 25,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were acquired at an average price of $13.00 per share, with a total value of $325,000.00. Following the acquisition, the insider now owns 31,298 shares in the company, valued at $406,874. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AGEN. Assenagon Asset Management S.A. boosted its stake in Agenus by 3,008.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after purchasing an additional 2,232,064 shares in the last quarter. Braidwell LP lifted its position in Agenus by 34.3% during the 3rd quarter. Braidwell LP now owns 6,307,030 shares of the biotechnology company’s stock worth $7,127,000 after buying an additional 1,609,100 shares in the last quarter. Pennant Investors LP bought a new stake in Agenus during the 4th quarter worth about $389,000. Vanguard Group Inc. increased its position in Agenus by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 26,938,439 shares of the biotechnology company’s stock valued at $30,440,000 after acquiring an additional 432,202 shares in the last quarter. Finally, Caxton Associates LP raised its stake in shares of Agenus by 247.3% in the third quarter. Caxton Associates LP now owns 390,234 shares of the biotechnology company’s stock worth $441,000 after acquiring an additional 277,863 shares during the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.